Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation

Inclusion Criteria: * 3DAA ABBVIE REGIMEN will be prescribed by physicians according to the routine clinical practice * Treatment-naïve or interferon (IFN)/ribavirin (RBV)-experienced participants with confirmed CHC Gt1b and compensated liver cirrhosis, receiving therapy with the interferon-free 3DAA ABBVIE REGIMEN initiated not earlier than 2 weeks before the enrollment or the initiation is planned not later than 2 weeks after the day of enrollment in accordance to standard of care and in line with the current local label * Participants must not be participating or intending to participate in a concurrent interventional therapeutic trial Exclusion Criteria: * Co-administration ribavirin (RBV) with the 3DAA ABBVIE REGIMEN * Participants with Child Pugh B and C cirrhosis * Participants with a history of prior direct-acting antiviral agent (DAA) therapy * Any other contraindications to the administration of 3DAA ABBVIE REGIMEN according to the label